Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Understanding Semaglutide (Ozempic) in CKD and T2D
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!The US Food and Drug Administration (FDA) approval of semaglutide 1.0 (Ozempic) for reducing the risk of kidney disease progression in type 2 diabetes marks a significant advance in the treatment landscape. To celebrate the approval and breakdown what the latest semaglutide approval means for clinicians and patients with type 2 diabetes, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.